


Lergotriple mesylate

Chemical Properties

CAS No. :	51473-23-5
Formula:	C ₁₈ H ₂₂ ClN ₃ O ₃ S
Molecular Weight:	395.9
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Lergotriple mesylate, an ergoline derivative, suppresses prolactin in vivo and in vitro.
Targets(IC50)	Others,Dopamine Receptor

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5259 mL	12.6295 mL	25.2589 mL
5 mM	0.5052 mL	2.5259 mL	5.0518 mL
10 mM	0.2526 mL	1.2629 mL	2.5259 mL
50 mM	0.0505 mL	0.2526 mL	0.5052 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Sherman BM, Swanson JA, Chapler FK. The treatment of hyperprolactinemia with a new ergot derivative, lergotriple mesylate. *Fertil Steril.* 1978 Mar;29(3):291-5. PubMed PMID: 565303.
- Clemens JA, Smalstig EB, Shaar CJ. Inhibition of prolactin secretion by lergotriple mesylate: mechanism of action. *Acta Endocrinol (Copenh).* 1975 Jun;79(2):230-7. PubMed PMID: 166535.
- Schmidt MJ. Dopamine agonist-induced hyperglycemia in rats: effects of lergotriple mesylate. *Eur J Pharmacol.* 1979 Oct 26;59(1-2):95-101. PubMed PMID: 41730.
- Lieberman A, Estey E, Kupersmith M, Gopinathan G, Goldstein M. Treatment of Parkinson's disease with lergotriple mesylate. *JAMA.* 1977 Nov 28;238(22):2380-2. PubMed PMID: 335094.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481